Brief: Sutro Biopharma Announces First Patient Dosed In Phase 1 Trial Of STRO-006
21/10/2026 13:23
BRIEF-Sutro Biopharma Announces First Patient Dosed In Phase 1 Trial Of STRO-006 Oct 21 (Reuters) - Sutro Biopharma Inc STRO.O:
SUTRO BIOPHARMA ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 TRIAL OF STRO-006, A NEXT-GENERATION ITGB6-TARGETING ADC, IN ADVANCED SOLID TUMORS
INITIAL CLINICAL DATA FOR STRO-006 EXPECTED IN SECOND HALF OF 2027
Source text: ID:nGNX8vK3SQ
Further company coverage: STRO.O
((Reutersbriefs@thomsonreuters.com;))
Recent news on Sutro Biopharma
See all newsBrief: Sutro Biopharma Announces First Patient Dosed In Phase 1 Trial Of STRO-006
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte
Sutro Biopharma Inc reports results for the quarter ended June 30 - Earnings Summary
Sutro Biopharma tumbles after missing estimates